Background: Ulcerative colitis (UC) is an inflammatory disease of the colon and rectum. Treatment options include biologics and tofacitinib. Objectives: We aim to summarize the evidence on efficacy and safety of biologics and tofacitinib in moderate-to-severe UC. Methods: PubMed, Embase, Scopus, and the Cochrane Library were systematically searched to identify meta-analyses of randomized controlled trials assessing adalimumab, golimumab, infliximab, vedolizumab, and tofacitinib in UC. Efficacy outcomes included induction and maintenance of clinical response, clinical remission and mucosal healing. Safety outcomes included adverse events and serious adverse events. Results: The overview involved 31 meta-analyses. All four biologics and tofacitinib were superior to placebo regarding efficacy. Indirect comparisons suggested that infliximab may be better than adalimumab and golimumab to induce clinical response and mucosal healing. Safety analyses indicated no increased rates of adverse events, except for infliximab. Conclusions: Biologics and tofacitinib are efficacious and safe for treating UC. These findings can support clinical decisionmaking.
Introduction
Ulcerative colitis (UC) is an inflammatory disease of the colon and rectum with remissions and relapses. Although the causes of UC have not been fully elucidated yet, its etiology comprises genetic and environmental factors. 1 UC is globally spread 2 with a high economic burden, which necessitates further research on its etiology and treatment. For instance, in the United States, where the prevalence of UC is 286 per 100,000 persons, 2 the total annual cost of the disease is between $8.1 and $14.9 billion. 3 The highest prevalence of UC has been observed in a European setting (Norway: 505 per 100,000). The cost of UC in Europe ranges between E12.5 and E29.1 billion. 3 UC is related with worsened quality of life, substantial morbidity and increased cancer risk. 4 Biologic therapies that include tumor necrosis factor (TNF) antagonists (adalimumab, ADA; golimumab, GLM; infliximab, IFX) and anti-a4b7 antibody (vedolizumab, VDZ) have improved the management of UC patients 5 compared with the conventional therapeutic approaches of 5-aminosalicylates, glucocorticoids and immunomodulators. Meanwhile, new treatment options are emerging. Tofacitinib (TFB), an orally administered small-molecule Janus kinase inhibitor, is a promising new medicine that has recently been approved by the regulatory authorities.
This work aims to systematically summarize the available evidence and provide an efficient overview of published meta-analyses (MAs) of randomized controlled trials (RCTs) on efficacy and safety of biologic agents and TFB, and hopefully to support clinical decision-making.
Materials and methods

Literature search
PubMed, Embase, Scopus and the Cochrane Library were systematically searched through December 2018. Search terms included: adalimumab, golimumab, infliximab, vedolizumab, tofacitinib, biologic(s), biologic(al) agent(s), ulcerative colitis and meta-analysis. Medical subject headings (MeSH) terms were also included. The search was limited to papers published in English and in international scientific journals. Conference abstracts were excluded as they usually present results of preliminary analyses, which later appear as full-text publications. The reference lists of the included MAs were screened to identify additional eligible publications that might have been missed by the electronic search.
Study selection
Eligible articles were MAs of RCTs that examined the efficacy and/or safety of biologic agents and TFB versus placebo for treatment of moderate-to-severe UC. MA should have reported the effect estimates for at least one of the efficacy outcomes, that is, clinical response, clinical remission, and mucosal healing and/or assessed safety based on any adverse event (AE) and serious adverse event (SAE), as defined in each MA. Both induction and maintenance phases were considered.
MAs of observational studies were not included as they provide a lower level of evidence than MAs of RCTs. As mentioned above, articles written in language other than English and conference abstracts were excluded.
Data selection and extraction
Two reviewers (KP and DE) independently screened titles and abstracts to identify potentially eligible MAs. Disagreements were resolved by consensus with a third reviewer (DP). Two reviewers (KP and DE) extracted the data from MAs; a third reviewer (AY) verified their accuracy. First author's last name, journal, year of publication, PROSPERO ID, type of agent and doses, patients' characteristics, outcomes examined, numbers of included RCTs and participants, estimated summary effect sizes along with the corresponding 95% confidence intervals (CI) or credible intervals (CrI), heterogeneity statistics, and statistics about small-study effects (p-value) were extracted from each MA. An I-square < 50% and Cochran's Q statistic p > 0.10 were considered as evidence of no substantial heterogeneity. The conduct of tests for smallstudy effects requires that at least 10 studies are included in a MA. 6, 7 Nevertheless, if tests for smallstudy effects were performed in MAs that had involved fewer than 10 studies, we presented their associated p-values. A p < 0.10 indicated the presence of smallstudy effects. In all other cases, a p < 0.05 was considered as statistically significant.
Quality of meta-analyses
Two reviewers (KP and AY) assessed the methodologic quality of each MA included in this overview based on AMSTAR 2. 8 AMSTAR 2 is an appraisal tool to assess systematic reviews of randomized trials and includes 16 items that combine several published guidelines on this issue (e.g. PRISMA, MOOSE). The AMSTAR 2 tool rates the overall confidence in a systematic review as high, moderate, low or critically low.
Results
Search results
The literature search yielded 766 records. In total, 31 MAs 9-39 met the eligibility criteria ( Figure 1 ). MAs of head-to-head trials were unavailable, hence we included network MAs presenting evidence from indirect comparisons. One study was in Chinese and excluded from the overview. 40 All eligible MAs were published after 2006. 14 Most MAs involved adult patients (18 years old) and patients naive to anti-TNF agents ( Supplementary Table S1 ).
The efficacy of biologic therapies in terms of clinical response, clinical remission and mucosal healing was studied in 28 MAs ( Supplementary Table S1 ). Two MAs presented data only for safety. 23, 26 Four MAs 9, 20, 29, 38 examined the combined effect of biologics. Induction therapy was examined in 25 MAs, maintenance therapy in 19 MAs, and the combination of induction and maintenance phases in three. 11, 16, 30 Primary maintenance studies considered in the included MAs that examined the efficacy and/or safety of golimumab and vedolizumab were restricted to induction responders who were re-randomized at the beginning of the study. This was not the case for adalimumab and infliximab trials.
Results of indirect comparisons between biologics were presented in 11 articles. 9, 10, 15, 17, 22, 24, 29, 31, 34, 35, 39 These articles provided efficacy estimates for indirect comparisons for the induction phase, while nine articles 9, 10, 15, 17, 22, 29, 31, 34, 39 did so also for the maintenance phase. AE were examined in 14 MAs and SAE in 19 MAs. Network MAs were reported in six articles. 15, [22] [23] [24] 31, 34 Tofacitinib was examined in four MAs 12,24,31,34 ( Supplementary Table S1 ). Clinical response was studied only when it was used as induction therapy. 12, 24 Most comparisons evaluated treatment effects using the odds ratio (OR) as the metric of choice. Relative risk (ReR) or Risk ratio (RiR) were also reported. One study 17 used a probit link function to estimate the treatment effect based on the change of the probit score of the control arm.
Quality assessment of meta-analyses
The quality of the included MAs was assessed as low (eight MAs, 25.8%) and critically low (23 MAs, 74.2%) ( Supplementary Table S2 ). Main critical flaws were the absence of a registered protocol for the MA (24 MAs, 77.4%) and of a list of the excluded studies with justification why these studies were not included in the MA (21 MAs, 67.7%).
Efficacy of biologics
Efficacy of biologics as induction therapy
Clinical
response. Meta-analyses 20,29 examining ADA, GLM, and IFX together in a direct comparison with placebo concluded that biologics were superior to placebo (Table 1A) .
ADA was individually examined in 12 MAs. The summary estimates showed that ADA is significantly better than placebo for dosages other than 80/40 mg subcutaneous (SC) (range of effect estimate: 1.28-1.98). Nine MAs studied the efficacy of GLM, 11 of IFX for intravenous use (IV), and nine of VDZ. All three biologics demonstrated superiority over placebo in all dosages (Table 1A) . Most indirect comparisons did not reach statistical significance ( Supplementary  Table S3 ). However, the indirect comparisons in the included MAs showed that IFX was significantly better than ADA (range of effect estimate: 1.46-2.44) and GLM (range of effect estimate: 1.60-1.67) ( Supplementary Table S3 ).
Clinical remission. ADA, GLM and IFX were examined together in two MAs. 20, 29 The results were statistically significant favoring these biologic agents over placebo (Table 1B) . The efficacy of ADA was investigated in 13 MAs. ADA administration improved clinical remission compared with placebo in most of these MAs (range of effect estimate: 1.10-2.22). Non-significant summary estimates were mainly obtained when only patients with prior exposure to anti-TNF agents were considered, 31,39 the number of participants was low, 20, 31, 36 or a dosage of 80/40 mg SC was administered. 20, 22, 36 GLM attained significant improvements in remission rates compared with placebo in most of the 10 MAs (range of effect estimate: 1.12-3.54). Fifteen MAs examined the efficacy of IFX indicating superiority over placebo (range of effect estimate: 1. 28-5.33) . VDZ was also found to be more effective than placebo in 11 MAs, except for UC patients with prior exposure to biologics (range of effect estimate: 1.18-4.51). The highest magnitude of effect was observed for IFX (Table 1B) . However, most indirect comparisons did not reach statistical significance ( Supplementary Table S3 ). About half of the MAs showed that IFX was significantly better than ADA (range of effect estimate: 2.10-3.03).
Clinical response/remission. One MA 17 examined the effect of ADA, GLM and IFX on clinical response and remission together. All three biologics were associated with beneficial treatment effects compared with placebo (Table 1C ). The indirect comparisons did not show statistically significant differences ( Supplementary Table S3 ).
Mucosal healing. Two MAs 9,20 examined the efficacy of all biologics together, showing superiority over placebo (Table 1D ). Summary effect estimates for ADA alone were reported in 13 MAs (17 comparisons). Of these, 12 comparisons showed that ADA was superior to placebo (range of effect estimate: 1.15-1.64). All comparisons in 10 MAs showed the superiority of GLM over placebo in terms of mucosal healing in the induction phase (range of effect estimate: 1.22-1.94), except for one comparison that was based on a dosage of 100/50 mg SC. 20 IFX comparisons with placebo for dosages 5 or 10 mg/kg IV indicated the superiority of the active comparator (range of effect estimate: 1.69-3.42). VDZ was significantly better than placebo in eight of 10 comparisons presented in eight MAs (range of effect estimate: 1.19-2.97). The two nonsignificant comparisons 31, 39 considered only UC patients with prior exposure to anti-TNF agents.
Nine of the 10 indirect comparisons indicated the superiority of IFX over ADA and four of nine comparisons suggested that IFX was better than GLM ( Supplementary Table S3 ).
Measures
of heterogeneity and small-study effects. Several MAs 9, 13, 14, 16, [18] [19] [20] 24, 25, 27, 29, [31] [32] [33] [35] [36] [37] [38] [39] provided heterogeneity assessment. Most comparisons versus placebo did not show substantial heterogeneity 16, 24, 32, 36 (Table 1A -D). In many cases, MAs included only one study or fewer than 10 studies, thus tests for small-study effects were not applicable.
Efficacy of biologics as maintenance therapy
Clinical response. MAs 20,29 that examined biologics together found that biologics were superior to placebo (Table 2A) .
Nine of 11 MAs for ADA and eight of 10 MAs for IFX showed a better clinical response over placebo in the maintenance phase. GLM and VDZ were also superior to placebo in all MAs except for one. 17 A few articles reported data on indirect comparisons among biologics ( Supplementary Table S4 ). Only one article 39 suggested the superiority of VDZ over IFX (IFX vs. VDZ, OR: 0.31, 95% CrI: 0.11-0.88).
Clinical remission. Three MAs 20,29,38 studied biologics together (Table 2B ) and found that they were more effective than placebo. One MA 38 included patients intolerant or refractory to conventional medical therapy but the superiority of biologics was confirmed.
Fourteen studies examined ADA individually. One 22 failed to reach statistical significance. Seven of 10 MA found that GLM was superior to placebo (range of effect estimate: 1.50-2.89). IFX was more effective than placebo in nine of 12 MAs, and VDZ was better than placebo in seven of eight MAs (range of effect estimate: 2.51-12.14). VDZ performed better than IFX (IFX vs. VDZ, OR: 0.34, 95% CrI: 0.12-0.97) only in one study 39 ( Supplementary Table S4 ). No other indirect comparisons reached statistical significance.
Mucosal healing. The combination of ADA and IFX showed superiority over placebo in one of two MAs. 20, 38 The four biologic agents were significantly better than placebo in one MA 9 (Table 2C ). IFX was significantly better than placebo in nine of 10 MAs (range of effect estimate: 1.52-3.90) and VDZ was significantly better than placebo in all MAs (range of effect estimate: 2.55-9.09). ADA and GLM were significantly better than placebo in all (13 MAs and six MAs, respectively) but two MAs.
In indirect comparisons, two of five MAs suggested that VDZ may be superior to ADA, and one of six that it may be superior to GLM. The significant effect estimates for ADA versus VDZ ranged from 0.15 to 0.46, and for GLM versus VDZ from 0.45 to 0.47 ( Supplementary Table S4 ).
Measures
of heterogeneity and small-study effects. Heterogeneity assessments for comparisons evaluating the efficacy of biologics as maintenance therapy were lacking. For most comparisons, no evidence of substantial heterogeneity was found, except for ADA and IFX combined, 20 and for GLM 24, 31 (Table 2A, B, and C) .
In many cases, MAs included only one study, or fewer than 10 studies. Consequently, tests for smallstudy effects were not applicable.
Efficacy of biologics as induction/maintenance therapy. Induction and/or maintenance therapy was examined in three MAs. 11, 16, 30 ADA, GLM and VDZ were more efficacious than placebo in most MAs (Table 3) . Non-significant differences from placebo were observed when the ADA dosage of 80/ 40 mg SC was administered. None of the articles reported indirect comparisons. Efficacy of tofacitinib. Tofacitinib was more effective than placebo in terms of clinical remission and mucosal healing in both the induction and maintenance phases. For the dosage of 10 mg as maintenance therapy, which was examined in two MAs, 31, 34 the difference regarding clinical remission was non-significant in one MA 31 (Table 4 ). One MA 31 showed that TFB was better than ADA in terms of clinical response and mucosal healing in the induction phase, when patients with prior exposure to anti-TNF agents were considered ( Supplementary Table S5 ). TFB also was found to perform better than ADA and GLM (dosages 50 or 100 mg) as maintenance therapy in one MA. 34 Safety Safety of biologics. Most MAs indicated that the examined biologics are safe compared with placebo both in terms of AE and SAE ( Supplementary Table  S6 ). However, two comparisons for IFX (AE) reached statistical significance; one for the induction phase (OR: 1.52, 95% CI: 1.03-2.24) 21 and one for the combined induction and/or maintenance phase (OR: 1.48, 95% CI: 1.00-2.19). 24 ADA showed a slightly elevated occurrence of AE in the maintenance phase (RiR: 1.28, 95% CI: 1.06-1.54) in one MA. In terms of indirect comparisons, no significant difference was observed between the biologics (Supplementary Tables S3, S4, S7) , except for a marginally significant difference in SAE between GLM and VDZ 24 ( Supplementary Table S7 ).
Safety of tofacitinib. All the MAs that examined TFB versus placebo have reported non-significant results ( Table 4 ). Indirect comparisons between TFB with biologics also yielded non-significant results ( Supplementary Table S5 ). 
Discussion
This overview summarized and evaluated the evidence from 31 MAs on the efficacy and safety of four biologic therapies and of a small-molecule agent in moderate-tosevere UC. More MAs involved ADA and IFX than GLM and VDZ, evaluated clinical remission rather than clinical response or mucosal healing, and presented results for the induction phase rather than for the maintenance phase. In biologic-naive patients, the existing evidence suggested that biologics are more effective than placebo. The safety of biologics in patients with UC had been documented in another overview 5 studying any infectious AEs, serious and opportunistic infections, tuberculosis and malignancies, concluding that treating UC patients with biologics is safe. Biologics were also found safe for treating UC in this overview. The only significant differences in terms of AEs (vs. placebo) were observed for IFX in the induction and induction/maintenance phases, and marginally for ADA in the maintenance phase. Indirect comparisons suggested that IFX may be better than ADA and GLM to induce clinical response, better than ADA in clinical remission, and superior to ADA and GLM in mucosal healing. Some of the evidence indicated that VDZ could be better than ADA and GLM in maintaining mucosal healing. These results are confirmed by the first study directly comparing two biologic agents in UC. 41 In this head-to-head comparison, VDZ was superior to ADA in achieving clinical remission and endoscopic mucosal healing at Week 52, while VDZ and ADA were both generally safe and well tolerated, in patients with moderate-tosevere UC. 41 The accumulated evidence for TFB showed that it was more effective than placebo, and indirect comparisons suggested its superiority over ADA and GLM for maintenance of remission and mucosal healing. No evidence was found for indirect comparisons between TFB and IFX.
This overview revealed some weaknesses in the field. Many MAs have been conducted, although the primary RCTs are rather few. Therefore, some MAs are based on a limited number of RCTs, undermining a major objective of MAs, which is to test for heterogeneity and small-study effects. Differences in definitions of outcomes in the included MAs may exist and cause variation in their summary effect estimates. There were not head-to-head comparisons between biologics or between biologics and TFB in the primary RCTs included in the MAs of this overview. Thus, the evidence was based on indirect comparisons. Significant parameters for MAs including heterogeneity and small-study effects statistics were often not reported even when enough RCTs were included. It is well known that earlier trials enrolled a higher proportion of (or exclusively) biologic-naive patients. For this reason, the estimates presented in network MAs mixing naive and non-naive populations should be interpreted with great caution. 42 Finally, many authors failed to register the protocol of their MA in advance and to provide a list of the primary studies excluded from MA and of the reasons why the authors did so.
In conclusion, this overview supports the efficacy and safety of biologics and TFB for the treatment of UC. IFX was superior than ADA and GLM for induction, and VDZ than ADA and GLM for maintaining mucosal healing. The superiority of VDZ over ADA was confirmed by a head-to-head trial. 41 IFX was the only agent showing an increase of AEs. TFB seems to be better than ADA and GLM for maintenance of remission and mucosal healing. This overview, as an in-depth summary of the existing evidence on the comparative efficacy and safety of therapeutic options for patients with UC, can support clinical decision-making. More studies on therapy combinations, early effective intervention, and precision medicine approaches are still needed to improve the management of non-naive patients. 42 More head-to-head trials are needed to 
